|
2024 Conference Publication EV430/#358 Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysisObermair, Andreas, West, Zoe, Baxter, Eva, Condous, George, Hacker, Neville, Lord, Sally, Mccarthy, Sandie, Janda, Monika, Tuffaha, Haitham, Hayes, Sandi, Disipio, Tracey, Mellon, Anne, Gebski, Val, Mcnally, Orla and Martin, Andrew (2024). EV430/#358 Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysis. IGCS 2024 Annual Meeting, Dublin, Ireland, 16-18 October 2024. London, United Kingdom: BMJ Group. doi: 10.1136/ijgc-2024-igcs.551 |
|
2024 Conference Publication Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)Horvath, L.G., Lin, H-M., Davis, I.D., Martin, A., Scheinberg, T., Meikle, P., Joshua, A., Mcjannett, M., Subhash, V., Yip, S., North, S., McDermott, R.S., Chi, K.N., Stockler, M.R. and Sweeney, C. (2024). Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.1688 |
|
2024 Conference Publication Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)Hamid, A.A., Thomas, H., Martin, A., Soon, Y.Y., Horvath, L.G., Zielinski, R., Thomson, A., Tan, H., Sandhu, S.K., Reaume, M.N., Pook, D.W., Parnis, F., McDermott, R.S., Lawrence, N., Frydenberg, M., Chi, K.N., Stockler, M.R., Davis, I.D. and Sweeney, C. (2024). Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.1699 |
|
2024 Conference Publication Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [<sup>177</sup>Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)Kwan, Edmond Michael, Hofman, Michael S., Ng, Sarah W. S., Emmett, Louise, Sandhu, Shahneen, Buteau, James Patrick, Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze Ting, Scott, Andrew Mark, Martin, Andrew James, Stockler, Martin R., Donnellan, Gráinne, Annala, Matti, Tolmeijer, Sofie H., Azad, Arun, Davis, Ian D., Wyatt, Alexander William and TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2024). Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May-4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.5055 |
|
2023 Conference Publication Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)Emmett, L., Subramaniam, S., Crumbaker, M., Joshua, A. M., Weickhardt, A. J., Lee, S. T., Ng, S., Francis, R. J., Goh, J. C. H., Pattison, D. A., Tan, H., Kirkwood, I. D., Sandhu, S. K., Nguyen, A., Gedye, C., Rutherford, N., Hofman, M., Martin, A., Stockler, M. R. and Davis, I. D. (2023). Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.10.086 |
|
2023 Conference Publication Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)Gedye, C., Harris, C. A., Stockler, M. R., Morris, M., Ferguson, T., Goh, J. C. H., Martin, A., Underhill, C. R., Pook, D., Krieger, L. E. M., Kichenadasse, G., Joshi, A. J., Subramaniam, S., Zebic, D. S., Zhang, A., Joshua, A. M., Toner, G. C., Vasey, P. A., Prithviraj, P. and Davis, I. D. (2023). Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.09.1116 |
|
2023 Conference Publication Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)Horvath, L. G., Davis, I. D., Martin, A., Zielinski, R., Thomson, A., Tan, T. H., Sandhu, S. K., Reaume, M. N., Pook, D., Parnis, F., North, S., Marx, G. M., McCaffrey, J. A., McDermott, R. S., Lawrence, N., Frydenberg, M., Chowdhury, S., Chi, K. N. N., Stockler, M. R. and Sweeney, C. (2023). Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.09.2742 |
|
2023 Conference Publication An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Tran, Ben, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Annual Meeting, Chicago, IL USA, 2-6 June 2023. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps5102 |
|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Ben Tran,, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Conference Publication Effects of [<SUP>177</SUP>Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysisSoon, Yu Yang, Marschner, Ian, Hofman, Michael S., Emmett, Louise, Davis, Ian D., Stockler, Martin R. and Martin, Andrew James (2023). Effects of [177Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-06, 2023. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2023 Conference Publication Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC)Hayne, Dickon, Stockler, Martin R., Martin, Andrew James, McCombie, Steve P., Zebic, Danka Sinikovic, Bastick, Patricia A., Beardsley, Emma Kate, Frydenberg, Mark, Green, William, Grummet, Jeremy, Hawks, Cynthia, Ischia, Joseph, Mitterdorfer, Andrew, Patel, Manish, Roberts, Matthew, Sengupta, Shomik, Srivastav, Ratnesh Kumar, Redfern, Andrew David and Davis, Ian D. (2023). Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Conference Publication SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivorsJefford, Michael, Emery, Jon D., Martin, Andrew James, Lourenco, Richard De Abreu, Lisy, Karolina, Mohamed, Mustafa Abdi, King, Dorothy, Tebbutt, Niall C., Lee, Margaret, Mehrnejad, Ashkan, Burgess, Adele, Marker, Julie, Eggins, Renee, Carrello, Joseph, Thomas, Hayley and Schofield, Penelope (2023). SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-06, 2023. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Tran, Ben, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps431 |
|
2023 Conference Publication Evolution: Phase II study of radionuclide <sup>177</sup>Lu-PSMA-617 therapy versus <sup>177</sup>Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Lee, Sze Ting, Weickhardt, Andrew James, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D., Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps271 |
|
2023 Conference Publication P3BEP (ANZUP 1302): an international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Ben Tran,, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): an international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs). Genitourinary Cancers Symposium, Virtual, 16-18 February 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Conference Publication Evolution:phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001)Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Weickhardt, Andrew James, Lee, Sze Ting, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D. and Emmett, Louise (2023). Evolution:phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001). Genitourinary Cancers Symposium, Virtual, 16-18 February 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2022 Conference Publication P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew, Pashankar, Farzana, Ben Tran,, Mazhar, Danish, Huddart, Robert, Wheater, Matthew, Walpole, Euan, Dunwoodie, Elaine, Feldman, Darren, Birtle, Alison, Stevanovic, Amanda G., Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2022). P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Clinical Oncology Society of Australia (COSA) 49th Annual Scientific Meeting, Brisbane, QLD, Australia, 2-4 November 2022. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.13869 |
|
2022 Conference Publication DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiationNiazi, Tamim, McBride, Sean Matthew, Williams, Scott, Davis, Ian D., Stockler, Martin R., Martin, Andrew James, Bracken, Karen, Roncolato, Felicia, Horvath, Lisa, Sengupta, Shomik, Martin, Jarad, Lim, Tee, Hughes, Simon, McDermott, Raymond S., Catto, James W. F., Kelly, Paul J., Parulekar, Wendy R., Morgan, Scott Carlyle, Rendon, Ricardo A. and Sweeney, Christopher (2022). DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.TPS284 |
|
2022 Conference Publication TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603)Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Zhang, Alison Yan, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Martin, Andrew James and Davis, Ian D. (2022). TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Virtual, 3-7 June 2022. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2022 Conference Publication ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)Emmett, Louise, Subramaniam, Shalini, Martin, Andrew James, Zhang, Alison Yan, Yip, Sonia, Crumbaker, Megan, Rana, Nisha, Francis, Roslyn J., Hofman, Michael S., Joshua, Anthony M., Sandhu, Shahneen Kaur, Azad, Arun, Gedye, Craig, Weickhardt, Andrew James, Goh, Jeffrey C., Ng, Siobhan, Voskoboynik, Mark, McJannett, Margaret Mary, Stockler, Martin R. and Davis, Ian D. (2022). ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.TPS205 |
